毒理性
在预先注册的临床试验中,治疗的患者中有小部分报告了血清酶升高,但没有报告出现临床上明显的肝损伤的实例。自从批准和使用更广泛的氧酸酯以来,没有已发布的因氧酸酯导致的肝损伤案例,并且在上市后不良反应的综述中并未列出肝毒性。因此,尽管使用高剂量(每日3至9克),氧酸酯引起的急性肝损伤极为罕见,如果真的发生的话。
In preregistration clinical trials, serum enzyme elevations were reported in small numbers of treated patients, but no instance of clinically apparent liver injury was reported. Since the approval and more widespread use of oxybate, there have been no published cases of liver injury due to oxybate, and in postmarketing overviews of adverse events hepatotoxicity was not listed. Thus, despite use in high doses (3 to 9 g daily), acute liver injury from oxybate must be very rare, if it occurs at all.
来源:LiverTox